EUCTR2014-005568-14-Outside-EU/EEA进行中（未招募）不适用
A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.
ovartis Pharma Services A.G.0 个研究点目标入组 225 人开始时间: 2015年6月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age = 37 weeks and a birth weight = 2.5 kg;
- •2. For whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
- •3. Available for all the visits scheduled in the study;
- •4. In good health as determined by medical history, physical examination and clinical judgment of the investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 225
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of any meningococcal vaccine administration;
- •2. Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), Pneumococcal, MMR (Measles, Mumps, Rubella) or varicella antigens;
- •3. Previous ascertained or suspected disease caused by N. meningitidis;
- •4. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis;
- •5. History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;
- •6. Significant acute or chronic infection within the previous 7 days or body temperature higher or equal to 38 C degrees within the previous day;
- •7. Antibiotics within 6 days prior to enrollment;
- •8. Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, insulin dependent diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);
- •9. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids since birth;
- •10. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation;
- •11. Receipt of, or intent to immunize with any other vaccine(s) (with the exception of rotavirus vaccine, influenza vaccine and second HepB vaccine), within 28 days prior and throughout the study period. Furthermore, subjects must have received HepB vaccine preferably at 0, 1 month of age, with the second dose at least 14 days prior to study vaccination. Influenza vaccine should be administered at least 14 days before or 14 days after study vaccination; Rotavirus vaccine may be administered during the study as per local practice.
- •12. Participation in another clinical trial since birth or planned for during study;
- •13. Family members and household members of research staff;
- •14. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
研究者
相似试验
已完成
3 期
OlympiADBreast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene MutationJPRN-jRCT2080222477AstraZeneca
进行中（未招募）
不适用
A study to assess the safety and efficacy of dexamethasone plus MLN9708 or physician choice of treatment in patients with relapsed or refacroty amyloidosis.Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisMedDRA version: 15.0Level: PTClassification code 10024459Term: Light chain diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005468-10-ITMILLENNIUM PHARMACEUTICALS, INC.248
进行中（未招募）
1 期
Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Therapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)Relapsed or refractory follicular lymphoma (FL) or marginal zona lymphoma (MZL)MedDRA version: 24.0Level: LLTClassification code 10029473Term: Nodular (follicular) lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004199-16-NLMEI Pharma, Inc.534
进行中（未招募）
1 期
Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Therapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)EUCTR2020-004199-16-GRMEI Pharma, Inc.534
已完成
3 期
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - The COASTAL StudyFollicular Lymphoma, Marginal zone lymphomaJPRN-jRCT2031230073Hanaya Miyoko534